Buy 5 or More Products! Save 25% On Total.
 Buy 3 or More Products! Save 10% On Total.
 Free Shipping! No Minimum Order.



Blog Empty Image

Which of the following inhibits CYP 3A4?

a. Omeprazole
b. Lansoprazole
c. Pantoprazole
d. Rabeprazole
e. Esomeprazole


Which of the following inhibits CYP 3A4?

a. Omeprazole
b. Lansoprazole
c. Pantoprazole
d. Rabeprazole
e. Esomeprazole

Answer: (a) Below is the list of drugs that inhibit specifically CYP 3A4:

1. Amiodarone
2. Anastrozole
3. Azithromycin
4. Cannabinoids
5. Cimetidine
6. Clarithromycin
7. Clotrimazole
8. Cyclosporine
9. Danazol
10. Delavirdine
11. Dexamethasone
12. Diethyldithiocarbamate
13. Diltiazem
14. Dirithromycin
15. Disulfiram
16. Entacapone (high dose)
17. Erythromycin
18. Ethinyl estradiol
19. Fluconazole
20. Fluoxetine
21. Fluvoxamine
22. Gestodene
23. Grapefruit juice
24. Indinavir
25. Isoniazid
26. Ketoconazole
27. Metronidazole
28. Mibefradil
29. Miconazole
30. Nefazodone
31. Nelfinavir
32. Nevirapine
33. Norfloxacin
34. Norfluoxetine
35. Omeprazole
36. Oxiconazole
37. Paroxetine (weak)
38. Propoxyphene
39. Quinidine
40. Quinine
41. Quinupristin and Dalfopristin
42. Ranitidine
43. Ritonavir
44. Saquinavir
45. Sertindole
46. Sertraline
47. Troglitazone
48. Troleandomycin
49. Valproic acid

Try our Naplex QBank. www.pharmacyexam.com


Blog Empty Image

Home ovulation tests usually detect a preovulatory surge in which of the following in the urine?

a. Prolactin
b. Oestrogen
c. Oxytocin
d. Progesterone
e. Luteinizing hormone


Home ovulation tests usually detect a preovulatory surge in which of the following in the urine?

a. Prolactin
b. Oestrogen
c. Oxytocin
d. Progesterone
e. Luteinizing hormone

Answer: (e). An ovulation home test is used by women to help determine the time in the menstrual cycle when getting pregnant is most likely. The test detects a rise in luteinizing hormone (LH) in the urine. A rise in this hormone signals the ovary to release the egg.

Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.


Blog Empty Image

Which of the following rating scales is commonly used to evaluate the severity of extrapyramidal symptoms (EPS)? [Select ALL that apply]

a. SAS
b. BARS
c. AIMS
d. ESRS
e. PDS


Which of the following rating scales is commonly used to evaluate the severity of extrapyramidal symptoms (EPS)? [Select ALL that apply]

a. SAS
b. BARS
c. AIMS
d. ESRS
e. PDS

Answer: (a,b,c,d). Extrapyramidal symptoms (EPS) are drug-induced movement disorders that include acute and tardive symptoms.

These symptoms include dystonia (continuous spasms and muscle contractions), akathisia (motor restlessness), Parkinsonism (characteristic symptoms such as rigidity, bradykinesia, and tremor), and tardive dyskinesia (irregular, jerky movements).

Since it is difficult to measure extrapyramidal symptoms, rating scales are commonly used to assess the severity of movement disorders.

The Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), Abnormal Involuntary Movement Scale (AIMS), and Extrapyramidal Symptom Rating Scale (ESRS) are rating scales frequently used for such assessment and are not weighted for diagnostic purposes.

Try our Naplex QBank. www.pharmacyexam.com


Blog Empty Image

Poison Ivy rash is an example of:

a. Type I Hypersensitivity
b. Type II Hypersensitivity
c. Type III Hypersensitivity
d. Type IV Hypersensitivity
e. Type V Hypersensitivity


Poison Ivy rash is an example of:

a. Type I Hypersensitivity
b. Type II Hypersensitivity
c. Type III Hypersensitivity
d. Type IV Hypersensitivity
e. Type V Hypersensitivity

Answer: (d), Type 4 hypersensitivity is often called delayed type. Delayed hypersensitivity does not start to be noticeable until several hours to a full day after exposure to the antigen. It may last for over a week.

Poison ivy rash is caused by an allergic reaction to an oily resin called urushiol (u-ROO-she-ol). This oil is in the leaves, stems and roots of poison ivy, poison oak and poison sumac. Urushiol, which is a hapten, when absorbed through the skin from a poison ivy plant, it (urushiol) undergoes oxidation in the skin cells to generate the actual hapten, a reactive molecule called a quinone, which then reacts with skin proteins to form hapten adducts.

T lymphocytes recognize the foreign substances, usually after the antigen is eaten, degraded, and presented (in pieces) by so-called antigen-presenting cells such as Langerhans cells in the skin, or macrophages. Urushiol metabolites (metabolite of Poison Ivy) are presented by this and other mechanisms. The T lymphocytes pour out inflammatory signal substances called cytokines. These call in armies of white blood cells called monocytes, which become macrophages. The macrophages become activated by the cytokines and attack everything in the vicinity, and can cause severe tissue damage.

Usually, the first exposure causes only sensitization, in which there is a proliferation of effector T-cells. After a subsequent, second exposure, the proliferated T-cells can become activated, generating an immune reaction that produces typical blisters of a poison ivy exposure.


In addition to poison ivy, a good example is the skin reaction to injected tuberculosis antigen. In fact, when tuberculosis bacteria infect the lung, it is the delayed hypersensitivity against them which destroys the lung. Unlike the other types, it is not antibody mediated but rather is a type of cell-mediated response.

https://www.pharmacyexam.com/images/questions/A7162.png

Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.


Blog Empty Image

Which of the following information about Zurampic is/are TRUE? [Select All that apply].

a. Acute liver failure has reported with Zurampic.
b. Zurampic should be used in combination with a xanthine oxidase inhibitor.
c. An active ingredient found in Zurampic is Lesinurad.
d. Zurampic is a xanthine oxidase inhibitor.
e. Zurampic is indicated for the treatment of hyperuricemia associated with gout.


Which of the following information about Zurampic is/are TRUE? [Select All that apply].

a. Acute liver failure has reported with Zurampic.
b. Zurampic should be used in combination with a xanthine oxidase inhibitor.
c. An active ingredient found in Zurampic is Lesinurad.
d. Zurampic is a xanthine oxidase inhibitor.
e. Zurampic is indicated for the treatment of hyperuricemia associated with gout.

Answer: (b,c,e). Zurampic (Lesinurad) is a URAT1 inhibitor. It is available as blue film-coated tablets for oral administration containing 200 mg Lesinurad. It should be used in combination with a xanthine oxidase inhibitor. Lesinurad reduces serum uric acid levels by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney. It is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

Zurampic (Lesinurad) is not recommended for the treatment of asymptomatic hyperuricemia. Zurampic (Lesinurad) should not be used as monotherapy.

Zurampic (Lesinurad) tablets are for oral use and should be co-administered with a xanthine oxidase inhibitor, including allopurinol or febuxostat. Zurampic (Lesinurad) is recommended at 200 mg once daily. This is also the maximum daily dose. Zurampic (Lesinurad) should be taken by mouth, in the morning with food and water.

Zurampic (Lesinurad) causes an increase in renal uric acid excretion, which may lead to renal events including transient increases in serum creatinine, renal-related adverse reactions, and kidney stones. These renal events occurred more frequently in patients receiving Zurampic (Lesinurad) 400 mg, when used as monotherapy or in combination with a xanthine oxidase inhibitor. Kidney function is required to monitor.

Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.


Blog Empty Image

Which of the following HMG-CoA inhibitors can be taken during any time of the day with or without food? [Select All that apply]

a. Atorvastatin
b. Pravastatin
c. Simvastatin
d. Pitavastatin
e. Rosuvastatin


Which of the following HMG-CoA inhibitors can be taken during any time of the day with or without food? [Select All that apply]

a. Atorvastatin
b. Pravastatin
c. Simvastatin
d. Pitavastatin
e. Rosuvastatin

Answer: (a,b,d,e).



Blog Empty Image

Which of the following information is/are TRUE about preparing TPN formulation? [Select ALL THAT APPLY].

a. A lipid emulsion in a three-in-one admixture obscures the presence of calcium phosphate precipitates.
b. The solubility of the added calcium should be calculated from the volume at the time the calcium is added and should NOT be based upon the final volume.
c. If the amount of calcium or phosphate which must be added is likely to cause a precipitate, some or all of the calcium should be administered separately.
d. If a three-in-one admixture is medically necessary, then add the calcium before the lipid emulsion.
e. When adding calcium and phosphate to an admixture, the calcium should be added first.


Which of the following information is/are TRUE about preparing TPN formulation? [Select ALL THAT APPLY].

a. A lipid emulsion in a three-in-one admixture obscures the presence of calcium phosphate precipitates.
b. The solubility of the added calcium should be calculated from the volume at the time the calcium is added and should NOT be based upon the final volume.
c. If the amount of calcium or phosphate which must be added is likely to cause a precipitate, some or all of the calcium should be administered separately.
d. If a three-in-one admixture is medically necessary, then add the calcium before the lipid emulsion.
e. When adding calcium and phosphate to an admixture, the calcium should be added first.

Answer: (a,b,c,d). TPN solutions are made according to a variety of formulations and compounding protocols. Thus, there are possibilities of calcium phosphate precipitates and many other chemical incompatibilities. Precipitates could develop because of a number of factors such as: the concentration, pH, and phosphate content of the amino acid solutions; the calcium and phosphorous additives; the order of mixing; the mixing process; or the compounder. The presence of a lipid emulsion in the TPN admixture would obscure the presence of any precipitate.

Because of the potential for life threatening events, caution should be taken to ensure that precipitates have not formed in any parenteral nutrition admixtures.

1. The amounts of phosphorous and of calcium added to the admixture are critical. The solubility of the added calcium should be calculated from the volume at the time the calcium is added. It should not be based upon the final volume.

Some amino acid injections for TPN admixtures contain phosphate ions (as a phosphoric acid buffer). These phosphate ions and the volume at the time the phosphate is added should be considered when calculating the concentration of phosphate additives. Also, when adding calcium and phosphate to an admixture, the phosphate should be added first.

2. The line should be flushed between the addition of any potentially incompatible components.

3. A lipid emulsion in a three-in-one admixture obscures the presence of a precipitate. Therefore, if a lipid emulsion is needed, either:

(1). use a two-in-one admixture with the lipid infused separately, or
(2). if a three-in-one admixture is medically necessary, then add the calcium before the lipid emulsion and according to the recommendations in number 1 above.

If the amount of calcium or phosphate which must be added is likely to cause a precipitate, some or all of the calcium should be administered separately. Such separate infusions must be properly diluted and slowly infused to avoid serious adverse events related to the calcium.

4. A filter should be used when infusing either central or peripheral parenteral nutrition admixtures. Standards of practice vary, but the following is suggested: a 1.2 micron air eliminating filter for lipid containing admixtures, and a 0.22 micron air eliminating filter for nonlipid containing admixtures.

Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.


Blog Empty Image

Which of the following is strong CYP1A2 inhibitor? [Select All that apply].

a. Fluvoxamine
b. Ciprofloxacin
c. Caffeine
d. Fluoxetine
e. Cimetidine


Which of the following is strong CYP1A2 inhibitor? [Select All that apply].

a. Fluvoxamine
b. Ciprofloxacin
c. Caffeine
d. Fluoxetine
e. Cimetidine

Answer: (a,b). Dose adjustments may be necessary in patients with concomitant use of:

Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin);

Moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine);

CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline);

CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John's wort, and rifampin); or

CYP1A2 inducers (e.g., tobacco smoking).

Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.


Blog Empty Image

With the ICD-10-PCS, the length of inpatient procedure codes are:

a. 7 alphanumeric characters
b. 3 alphanumeric characters
c. 13 alphanumeric characters
d. 10 alphanumeric characters
e. 17 alphanumeric characters


With the ICD-10-PCS, the length of inpatient procedure codes are:

a. 7 alphanumeric characters
b. 3 alphanumeric characters
c. 13 alphanumeric characters
d. 10 alphanumeric characters
e. 17 alphanumeric characters

Answer: 7 alphanumeric characters. The U.S. Department of Health and Human Services (HHS) announced a final rule that will facilitate the United States' ongoing transition to an electronic health care environment through adoption of new healthcare code sets for use in electronic health care transactions. This rule adopts updated versions of the code sets, under the authority of HIPAA (ICD-10 final rule). The ICD-10 code sets replace the ICD-9-CM code set.

In past, the industry was using about 4,000 unique ICD-9-CM volume 3 codes to describe inpatient procedures. ICD-9 procedure codes were 3-4 digits in length (e.g., 47.01 - Laparoscopic appendectomy). With the ICD-10-PCS mandate, the length of inpatient procedure codes increase to 7 alphanumeric characters (e.g., ODTJ4ZZ - Laparoscopic appendectomy).

Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.


Blog Empty Image

Which of the following information is/are TRUE about Durlaza?

I. Clopidogrel is an active ingredient.

II. Indicated for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack).

III. Available as 24-hour, extended release capsules formulation containing 162.5mg active ingredient.

a. I only
b. III only
c. I and II only
d. II and III only
e. All


Which of the following information is/are TRUE about Durlaza?

I. Clopidogrel is an active ingredient.

II. Indicated for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack).

III. Available as 24-hour, extended release capsules formulation containing 162.5mg active ingredient.

a. I only
b. III only
c. I and II only
d. II and III only
e. All

Answer: (d) II and III are true. Durlaza is an aspirin formulation for secondary prevention in high-risk CVD patients. The aspirin delivery technology in Durlaza extends the release of aspirin in a manner designed to provide a stable antiplatelet effect over the course of the day.

Low-dose aspirin has been proven to reduce the risk of secondary cardiovascular events and mortality in high-risk patients with stable cardiovascular disease. This is primarily due to aspirin's ability to inhibit platelet aggregation (blood clotting).

While the body is making platelets 24-hours a day, current immediate-release traditional aspirin only stays in the blood for about a mean duration of four to six hours, with peak plasma concentrations peaking after just 30 minutes.

Durlaza utilizes extended-release, microcapsule technology to prolong aspirin release. Durlaza offers the only once-daily, 24-hour antiplatelet therapy through the extended release of its 162.5mg dose, resulting in prolonged absorption, and sustained platelet exposure to aspirin. Durlaza, like immediate-release aspirin, increases the risk of bleeding and gastric ulceration, and may cause fetal harm when administered to a pregnant woman.

Try our Naplex QBank. www.pharmacyexam.com




Free USA Shipping! No Minimum Order.
Free International Shipping! Over $350 or More.